|
| << previous | next >> |
Journal description
All volumes of the corresponding journal
All issues of the corresponding volume
All articles of the corresponding issues
Details for article 32 of 51 found articles
| Title: |
Mucosal immune response induced by proteoliposome and cochleate derived from serogroups B N. meningitidis |
| Author: |
Judith del Campo Miriam Lastre Caridad Zayas Reinaldo Acevedo Elizabeth González Belkis Romeu Maribel Cuello Osmir Cabrera Julio Balboa, Ali M. Sarandi Oliver Pérez |
| Appeared in: |
VacciMonitor |
| Paging: | Volume 18 (2009) nr. 2 pages 71-74 |
| Year: |
2009 |
| Contents: |
Mucosal vaccination offers attractive advantages to conventional systemic vaccination. Most pathogens enter or establish infection at mucosal surfaces. This represents an enormous challenge for vaccine development.Nevertheless, the availability of safe and effective adjuvants that function mucosally is the major limitation.Therefore, we investigated the impact of mucosal immunization with the Neisseria meningitidis B proteoliposome (AFPL1, Adjuvant Finlay Proteoliposome 1) and its-derived cochleate (Co, AFCo1). They contain multiple PAMPs as immunopotentiators and have delivery system ability as well as Th1 polarization activity. Groups of female mice were immunized by nasal, oral, intravaginal, or intramuscular routes with three doses with AFPL1/AFCo1 alone orcontaining ovalbumin or glycoprotein (g) D2 from Herpes Simplex Virus type 2 (HSV-2). High levels of specific IgGantibodies were detected in sera of mice vaccinated with either route. However, specific IgA antibodies were produced in saliva and vaginal wash only following mucosal delivering. The polarization to a Th1 pattern was confirmed by testing the induction of IgG2a/IgG2c antibody, positive delayed-type hypersensitivity reactions, andgIFN production. Additionally, AFCo1gD2 showed practically no vaginal HSV-2 replication and 100% protection against lethal vaginal HSV-2 challenge. In conclusion, the results support the use of AFCo1 as potent Th1 adjuvant for mucosal vaccines, particularly for nasal route. |
| Publisher: |
Finlay Ediciones (provided by DOAJ) |
| Source file: |
Elektronische Wetenschappelijke Tijdschriften |
Details for article 32 of 51 found articles
| << previous | next >> |